Clinical trial

Immunogenicity and Safety of Adsorbed Diphtheria, Tetanus, Acellular Pertussis Combined Vaccine or Adsorbed Diphtheria Tetanus Combined Vaccine in 6 Years Old Children:a Randomized, Controlled Clinical Study

Name
DTaP/DT-2023-01
Description
This study is to evaluate the immunogenicity and safety of DTaP or DT given in children aged 6 years.
Trial arms
Trial start
2023-05-01
Estimated PCD
2023-12-01
Trial end
2024-11-01
Status
Not yet recruiting
Phase
Early phase I
Treatment
vaccinate with DTap
vaccinate with DTap
Arms:
Group A
vaccinate with DT
vaccinate with DT
Arms:
Group B
Size
480
Primary endpoint
Seroconversion rates of the vaccination
28-42 days after the dose of DTaP or DT
Seropositive rates after the vaccination
28-42 days after the dose of DTaP or DT
Eligibility criteria
Inclusion Criteria: 1. Participants aged ≥ 6 on the day of enrollment; 2. Informed consent should be signed and dated by the participants; 3. The participant's legal guardian is able to attend all planned follow-up visits and comply with all study procedures; 4. The participants have received 4 doses of acellular TDap vaccine and have not received any immunization agents related to diphtheria, tetanus, and pertussis in the past 3 years; 5. The participant has no diease history of pertussis, diphtheria or tetanus; 6. ≥ 14 days interval between the last vaccination; 7. Body temperature was ≤37.3℃. Exclusion Criteria: 1. Being allergic to any component of vaccines ; 2. A history of severe allergic reactions to any vaccine (for example acute allergic reaction, angioneurotic edema, dyspnea, etc); 3. Having a history or family history of convulsions, encephalopathy, psychosis, uncontrolled epilepsy and other progressive neurological diseases; 4. Participants are suffering from immunodeficiency, receiving immunosuppressant therapy (oral steroid hormones) during treatment for malignancy, or having low immunity due to HIV, or having congenital immune disorders in close family members; 5. Injection of non-specific immunoglobulin within 1 month before enrollment; 6. Participants are suffering from acute febrile diseases and infectious diseases; 7. A history of clearly diagnosed thrombocytopenia or other clotting disorders that may contraindicate subcutaneous injection; 8. Participants with severe chronic diseases or acute episodes of chronic diseases; 9. Participants with infectious, suppurative and allergic skin diseases; 10. Other Participants whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 480, 'type': 'ESTIMATED'}}
Updated at
2023-05-23

1 organization

2 products

1 indication

Product
DTap
Product
DT Vaccine